10x Genomics(NASDAQ) TXG

Current Price$46.79

Market Cap$5.99B

Since IPO (2019)-11%

5 Year-75%

1 Year+309%

1 Month+36%

10x Genomics last closing stock price
Metric	Price	Date
Last close	USD 47.20	2026-07-21

10x Genomics stock price return by period
Period	Price return	Price at period start	Period start date
1 week	+3.08%	USD 45.79	2026-07-14
1 month	+35.81%	USD 34.76	2026-06-18
3 month	+106.75%	USD 22.83	2026-04-22
Year to date	+189.39%	USD 16.31	2025-12-31
1 year	+309.01%	USD 11.54	2025-07-21
3 year	-21.28%	USD 59.96	2023-07-21
5 year	-74.61%	USD 185.89	2021-07-22
Since inception	-10.52%	USD 52.75	2019-09-12

10x Genomics Financials at a Glance

Market Cap

$5.99B

Revenue (TTM)

$638.78M

Net Income (TTM)

-$22.66M

EPS (TTM)

-$0.17

P/E Ratio

-270.64

Dividend

$0.00

Beta (Volatility)

2.06 (High)

Dividend

$0.00

Beta (Volatility)

2.06 (High)

Price

$46.79

Volume

2,822,554.223

Open

$46.59

Price

$46.79

Volume

2,822,554.223

Open

$46.59

Previous Close

$47.05

Daily Range

$45.96 - $47.85

52-Week Range

$11.16 - $47.85

Estimated Earnings Date

Aug 6, 2026

Dividend

$0.00

Beta (Volatility)

2.06 (High)

Price

$46.79

Volume

2,822,554.223

Open

$46.59

Previous Close

$47.05

Daily Range

$45.96 - $47.85

52-Week Range

$11.16 - $47.85

Estimated Earnings Date

Aug 6, 2026

TXG News

Medical-gloved hand holding human DNA in front of sequence imaging.jpg

4 Best Genetic Sequencing Stocks for 2026 and How to Invest

Keith SpeightsJul 13, 2026

A scientist looking through a microscope.

5 Best Biotech ETFs for 2026 and How to Invest

Keith SpeightsJul 10, 2026

10x Genomics CEO Sells Nearly 30,000 Shares. Here's What That Means for Investors.

Robert IzquierdoJun 1, 2026

This $4 Million Bet Shows Growing Confidence in 10x Genomics as Stock Surges 116%

Jonathan PoncianoMay 12, 2026

Doctor holding clipboard stands with virtual DNA double helix in the air near him.

Best Genomics Stocks for 2026 and How to Invest

Lyle DalyApr 18, 2026

Page 1

TXG: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About 10x Genomics

10x Genomics makes tools that help scientists study the smallest parts of living things. These products let researchers look at individual cells to understand how diseases work. Scientists in labs and drug companies use these systems to make new medical discoveries.

Tools for Looking at Cells

Chromium Instruments: Hardware used for single cell analysis to measure gene activity and immune cell targets.
Spatial Analysis Systems: Visium and Xenium platforms that map where specific biological activity happens within a tissue sample.
Consumables: Proprietary chips, reagents, and slides required to run tests; accounted for 86% of total revenue in Q1 2026.
Software and Services: Data visualization programs and instrument maintenance plans; services revenue grew 15% in Q1 2026.

Strategic Deals and Disputes

Acquired Scale Biosciences, Inc. in August 2025 to expand single cell technology offerings.
Purchased assets from Centrillion Technologies, Inc. and Centrillion Technology Holdings Corp. starting in 2023 for technology development.
Settled worldwide patent disputes with Vizgen, Inc. and Bruker in 2025, leading to new license and royalty agreements.
Filed patent infringement lawsuits against Illumina, Inc. in October 2025 regarding both spatial and single cell technologies.

Operational Strengths

The company uses a razor and blade business model that requires customers to buy proprietary supplies for every experiment. It maintains a global reach with subsidiaries in North America, Europe, and Asia to serve large research institutions.

The Quarterly Results

Total revenue was $150.8 million in Q1 2026, down 2.6% from the same period in 2025.
Net loss narrowed to $13.5 million in Q1 2026, a 60.8% improvement from the $34.4 million loss a year earlier.
Spatial consumables revenue reached $40.9 million in Q1 2026, up 31% year-over-year.
Free cash flow turned positive at $24.5 million in Q1 2026, up from an $18.6 million outflow in Q1 2024.

Bottom Line

10x Genomics is moving from selling hardware to earning recurring revenue through its specialized testing supplies. The settlement of major legal battles and growth in spatial mapping technology have helped the company significantly narrow its operating losses.

AI Generated • May 24, 2026

Industry

Life Sciences Tools and Services

Sector

Health Care

Employees

1,178

CEO

Serge Saxonov, PhD

Website

www.10xgenomics.com

Headquarters

Pleasanton, CA 94588-3260, US

TXG Financials

Key Financial Metrics (TTM)

Gross Margin

69.60%

Operating Margin

-6.06%

Net Income Margin

-3.55%

Return on Equity

-2.86%

Return on Capital

-11.62%

Return on Assets

-2.23%

Earnings Yield

-0.37%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$5.99B

Shares Outstanding

126.96M

Volume

2.82M

Avg. Volume

3.16M

Financials (TTM)

Gross Profit

$444.61M

Operating Income

-$38.70M

EBITDA

$93.30M

Operating Cash Flow

$127.82M

Capital Expenditure

-$5.64M

Free Cash Flow

$122.18M

Cash & ST Invst.

$539.85M

Total Debt

$81.39M

10x Genomics Performance Analysis

10x Genomics annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	USD 516,409,000	5.3%
2023	2023-12-31	USD 618,727,000	19.8%
2024	2024-12-31	USD 610,785,000	-1.3%
2025	2025-12-31	USD 642,823,000	5.2%

10x Genomics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	11.6%
Q3	2025-09-30	-13.8%
Q4	2025-12-31	11.4%
Q1	2026-03-31	-9.1%

10x Genomics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	USD -1.46	176.3%
2023	2023-12-31	USD -2.18	49.3%
2024	2024-12-31	USD -1.52	-30.4%
2025	2025-12-31	USD -0.35	-77.0%

10x Genomics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	200.0%
Q3	2025-09-30	-178.6%
Q4	2025-12-31	40.9%
Q1	2026-03-31	23.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

$150.84M

-2.6%

Gross Profit

$106.18M

+0.7%

Gross Margin

70.39%

N/A

Market Cap

$5.99B

N/A

Market Cap/Employee

$5.09M

N/A

Employees

1,178

N/A

Net Income

-$13.47M

+60.8%

EBITDA

-$937.00K

+96.0%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Total Cash

$539.85M

+26.5%

Total Debt

$81.39M

+1.6%

Accounts Receivable

$56.14M

+6.8%

Inventory

$53.49M

-28.4%

Long Term Debt

$70.06M

-0.8%

Short Term Debt

$11.33M

+20.0%

Return on Assets

-2.23%

N/A

Return on Invested Capital

-4.29%

N/A

Free Cash Flow

$24.52M

-24.4%

Operating Cash Flow

$26.12M

-24.0%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

GRDNGuardian Pharmacy Services, Inc.

GRDNGuardian Pharmacy Services, Inc.$39.77-2.79%

PGNYProgyny, Inc.

PGNYProgyny, Inc.$31.35-2.76%

NUVBNuvation Bio Inc.

NUVBNuvation Bio Inc.$6.55+1.87%

SIONSionna Therapeutics, Inc.

SIONSionna Therapeutics, Inc.$45.03-4.62%

OMCLOmnicell, Inc.

OMCLOmnicell, Inc.$40.86-2.32%

TDOCTeladoc Health, Inc.

TDOCTeladoc Health, Inc.$8.92-8.14%

OMDAOmada Health

OMDAOmada Health$21.84-5.00%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

TAT&T

TAT&T$23.04+0.04%

ONDSOndas

ONDSOndas$8.00+0.04%

SMCISuper Micro Computer

SMCISuper Micro Computer$30.56+0.20%

AALAmerican Airlines Group

AALAmerican Airlines Group$14.79-0.03%

PATHUiPath

PATHUiPath$10.70-0.11%

NOKNokia

NOKNokia$10.28-0.03%

SOFISoFi Technologies

SOFISoFi Technologies$17.07-0.03%

Questions About TXG

What is the current price of 10x Genomics?

10x Genomics is trading at $47.05 per share.

What is the 52-week range for 10x Genomics?

Over the past 52 weeks, 10x Genomics has traded between $11.16 and $47.85.

How much debt does 10x Genomics have?

As of the most recent reporting period, 10x Genomics reported total debt of $81.39M.

How much cash does 10x Genomics have on hand?

10x Genomics reported $490.29M in cash and cash equivalents in its most recent financial results.

What is 10x Genomics’s dividend yield?

10x Genomics does not currently have a dividend yield.

10x Genomics(NASDAQ) TXG

10x Genomics Financials at a Glance

TXG News

4 Best Genetic Sequencing Stocks for 2026 and How to Invest

5 Best Biotech ETFs for 2026 and How to Invest

10x Genomics CEO Sells Nearly 30,000 Shares. Here's What That Means for Investors.

This $4 Million Bet Shows Growing Confidence in 10x Genomics as Stock Surges 116%

Best Genomics Stocks for 2026 and How to Invest

Lancaster Opens $7 Million Position in 10x Genomics (TXG)

Why 10x Genomics Stock Was Sliding This Week

10x Genomics Misses Revenue Forecast

TXG: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About 10x Genomics

Tools for Looking at Cells

Strategic Deals and Disputes

Operational Strengths

The Quarterly Results

Bottom Line

TXG Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

10x Genomics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About TXG

What is the current price of 10x Genomics?

What is the 52-week range for 10x Genomics?

How much debt does 10x Genomics have?

How much cash does 10x Genomics have on hand?

What is 10x Genomics’s dividend yield?

Premium Investing Services